5-MeO-PiPT

5-Methoxy-N-propyl-N-isopropyltryptamine (5-MeO-PiPT) is a substituted tryptamine derivative which is claimed to have psychedelic effects. It acts as a 5-HT2A receptor agonist, with an EC50 of 13.8 nM and an efficacy of 89% (vs 5-HT),[1] and has been sold as a designer drug, first being identified in 2021 in British Columbia, Canada.[2]

5-MeO-PiPT
Identifiers
  • N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-N-(propan-2-yl)propan-1-amine
Chemical and physical data
FormulaC17H26N2O
Molar mass274.408 g·mol−1
3D model (JSmol)
  • CC(C)N(CCC)CCc1c[NH]c2ccc(cc21)OC
  • InChI=1S/C17H26N2O/c1-5-9-19(13(2)3)10-8-14-12-18-17-7-6-15(20-4)11-16(14)17/h6-7,11-13,18H,5,8-10H2,1-4H3
  • Key:KLRSMSBDLVDLKK-UHFFFAOYSA-N

See also

References
  1. Banister S, Jorgensen W, Jinlong T. Compounds. Patent WO 2023/115167
  2. Knill A, Tobias S, Matthews J, Ti L (June 2022). A Report on British Columbia’s Unregulated Drug Supply. Drug checking trends across British Columbia, January to December 2021 (PDF). British Columbia Centre on Substance Use (Report).


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.